IL1RL1 and asthma: TQC2938 can specifically bind to human ST2, block its interaction with IL-33 ligand, block the ST2/IL-33 signaling pathway, reduce the production of downstream Th2 cytokines (such as IL-4, IL-5, and IL-13), reduce the level of eosinophils and other inflammatory cells, and reduce the occurrence of asthma, improving the quality of life of patients.